

HONOReform (Hepatitis Outbreaks' National Organization for Reform) began as a response to a tragedy. Evelyn McKnight and 98 other cancer patients in rural Fremont, Nebraska, were infected with hepatitis in 2001. The cause? Healthcare providers failed to follow injection safety practices when providing treatment.
Far from an isolated event, the Nebraska outbreak is one of 35 documented outbreaks in non-hospital settings in America between 1998-2008. Patients from all walks of life who were receiving care for multiple conditions in a wide variety of health care settings have been infected with bloodborne pathogens, including HCV (hepatitis C).
HONOReform is working at all levels – from local communities to Capitol Hill – to save lives by ensuring that fundamental injection safety practices are followed each and every time. The HONOReform mission is shaped by a three-pronged commitment to safety:
• Safety by Design through adoption of safe injection devices that are engineered to remove human error;
• Safety by Incentives to spur on faster adoption of infection control guidelines by healthcare professionals and administrators;
• Safety by Education and reeducation of healthcare workers regarding infection control – and empowerment of patients to ask questions and report concerns.
By building safeguards into the injection process, incentivizing health care providers at all levels to universally follow fundamental safety standards, and educating and reeducating providers, all patients will be protected all the time. To achieve this goal, HONOReform works with healthcare stakeholders – including elected leaders, public health officials, patients, providers and industry – to make sure lessons are learned, standard practices are followed and lives are saved.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close